The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive alternative to glasses or surgery. Phase 3 trials demonstrated superior ...
The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod ...
The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...
Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...
Opus Genetics is conducting a trial for OPGx-MERTK gene therapy in Abu Dhabi, targeting MERTK-related retinitis pigmentosa using AAV-based delivery. The trial is a collaboration with Cleveland Clinic ...
The study highlights the importance of shear-thinning behavior in artificial tears, crucial for mimicking natural tear properties and ensuring ocular surface protection. Hyaluronic acid's ...
Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in ...
Retinal imaging during ROP screening can predict bronchopulmonary dysplasia and pulmonary hypertension in preterm infants, ...
The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...
Glaucoma specialists are marking their calendars for January 31, 2026—when the 2nd International Glaucoma Symposium will take ...
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...
Prostaglandin analogues, such as latanoprost and bimatoprost, are the go-to therapies for glaucoma therapy. They continue to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results